Current Diabetes Reports

, Volume 10, Issue 3, pp 176–183

Are Analogue Insulins Superior to Human Insulin in Clinical Practice?



Insulin analogues were designed to provide more physiologic pharmacokinetic and pharmacodynamic properties compared with human insulin. This article examines the literature over a 2-year period, focusing on studies directly comparing analogue and human insulin in controlled clinical trials and large observational studies documenting the introduction of, or change to, analogue insulin in clinical practice. Findings indicate that analogues provide objective benefits that include improved glycemic control, lower risk of hypoglycemia, lower glucose variability, and (for insulin detemir) reduced weight gain. Recent data with analogues also explore their safety and efficacy in special patient groups such as children and adolescents. These data complement increasing evidence that analogues offer improved acceptability and accessibility to people with diabetes.


Analogue insulin Premixed insulin Biphasic insulin 

Clinical Trial Acronyms


Achieving control through insulin plus oral agents


Observational study of safety and effectiveness of NovoMix 30 for the treatment of diabetes mellitus


Observational, safety study in subjects using Levemir® (Insulin detemir) for the treatment of insulin dependent type 1 or type 2 diabetes mellitus


Physicians’ routine evaluation of safety and efficacy of NovoMix 30 therapy

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Endocrinology of the Department of Internal Medicine, Division of Endocrinology and MetabolismPhiladelphia College of Osteopathic MedicinePhiladelphiaUSA

Personalised recommendations